The stock of Fate Therapeutics Inc (NASDAQ:FATE) is a huge mover today! About 404,643 shares traded hands or 351.27% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has declined 4.02% since April 11, 2016 and is downtrending. It has underperformed by 10.16% the S&P500.
The move comes after 7 months positive chart setup for the $97.78 million company. It was reported on Nov, 11 by Barchart.com. We have $3.95 PT which if reached, will make NASDAQ:FATE worth $33.25 million more.
Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage
Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Wells Fargo on Friday, December 4. The company was initiated on Thursday, September 22 by Roth Capital. On Tuesday, November 8 the stock rating was maintained by Wedbush with “Outperform”. The firm has “Buy” rating by TH Capital given on Thursday, September 22. BMO Capital Markets initiated it with “Outperform” rating and $4 target price in Tuesday, April 12 report. On Tuesday, October 6 the stock rating was initiated by Raymond James with “Outperform”.
According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”
Insitutional Activity: The institutional sentiment decreased to 0.56 in 2016 Q2. Its down 0.40, from 0.96 in 2016Q1. The ratio turned negative, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.
Blackrock Investment Ltd Llc, a New Jersey-based fund reported 4,327 shares. Financial Bank Of New York Mellon holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 68,444 shares. Polaris Venture V Lc accumulated 2.47M shares or 4.51% of the stock. Kingdon Mgmt Ltd Co owns 2.26M shares or 0.21% of their US portfolio. Blackrock Advsr Ltd Liability Corporation reported 4,030 shares or 0% of all its holdings. Redmile Grp Limited Liability Com has invested 0.24% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Tocqueville Asset Lp reported 22,000 shares or 0% of all its holdings. Bridgeway Capital Mgmt last reported 0.01% of its portfolio in the stock. Blackrock Institutional Tru Communications Na accumulated 5,728 shares or 0% of the stock. Belmont Glob Advisors Inc holds 0.65% or 400,000 shares in its portfolio. Bancorp Of Montreal Can reported 285 shares or 0% of all its holdings. Deutsche Bancorp Ag holds 17,792 shares or 0% of its portfolio. Lombard Odier Asset Mngmt (Usa) Corp, a New York-based fund reported 256,426 shares. Da Davidson And, a Montana-based fund reported 720 shares. Nationwide Fund Advsr reported 22,578 shares or 0% of all its holdings.
More recent Fate Therapeutics Inc (NASDAQ:FATE) news were published by: Seekingalpha.com which released: “Fate Therapeutics’ (FATE) CEO Scott Wolchko on Q3 2016 Results – Earnings Call …” on November 08, 2016. Also 247Wallst.com published the news titled: “Could This Be a Turning Point for Fate Therapeutics?” on June 20, 2016. Globenewswire.com‘s news article titled: “Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch …” with publication date: September 07, 2016 was also an interesting one.
FATE Company Profile
Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.